张冕;王蔼明;

• 1:中国人民解放军总医院第六医学中心妇产科

摘要(Abstract)：

目的:比较PPOS方案与拮抗剂方案对卵巢低反应患者行IVF-ET助孕治疗的临床效果,探讨两种超促排卵方案在卵巢低反应(POR)患者中的疗效差异。方法:回顾分析2014年5年至2018年5月在解放军总医院第六医学中心辅助生殖医学中心行IVF-ET助孕治疗的POR患者的临床资料,根据促排卵方案不同分为PPOS组(实验组,48个周期)和拮抗剂组(对照组,67个周期)。比较两组患者的基本情况、助孕效果及妊娠结局。结果:两组患者的基本情况、基础激素水平、HCG日激素水平(FSH、P、E_2)、HCG日≥10mm卵泡数、获卵数、正常受精数、Day3优胚数、可用胚胎数、妊娠率、临床妊娠率、流产率比较,差异均无统计学意义(P>0.05)。PPOS组的HCG日血清LH水平明显低于拮抗剂组,差异有统计学意义[(2.88±2.56)mIU/ml vs (4.51±4.26)mIU/ml,P<0.05];PPOS组Gn用药总量、用药天数均多于拮抗剂组,差异有统计学意义[(2210.42±766.88)IU vs (1747.01±764.98)IU;(10.88±3.21)d vs (9.12±3.14)d,P<0.05]。PPOS方案组的获卵率、正常受精率、Day3优胚率、妊娠率、临床妊娠率与拮抗剂方案组相比无统计学差异,但总体上,均为PPOS组更理想(81.8%vs 71.1%、61.2%vs 58.2%、74.3%vs 73.2%、29.6%vs 16.3%、18.5%vs 10.5%)。PPOS组的周期取消率(14.58%)低于拮抗剂方案组(34.33%),差异有统计学意义(P<0.05)。结论:PPOS方案能更有效控制早发LH峰,使周期取消率更低,降低了治疗费用,有较好的临床价值。

关键词(KeyWords)： PPOS方案;拮抗剂方案;卵巢低反应;IVF-ET

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 张冕;王蔼明;

DOI: 10.13283/j.cnki.xdfckjz.2019.09.006

参考文献(References)：

• [1] Polyzos NP,Devroey P.A systematic review of randomized trials for the treatment of poor ovarian responders:is there any light at the end of the tunnel?[J].Fertil Steril,2011,96(5):1058-1061.el
• [2] Bosdou JK,Venetis CA,Kolibianakis EM,et al.The use of androgens or androgen-modulating agents in poor responders undergoing in vitro fertilization:a systematic review and meta-analysis[J].Hum Reprod Update,2012,18(2):127-145
• [3] 徐阳,张阳阳.控制性超促排卵后卵巢低反应的诊断及治疗[J].国际生殖健康/计划生育杂志,2015,34(6):519-523
• [4] Ferraretti AP,La Marca A,Fauser BC,et al.ESHRE consensus on the definition of'poor response'to ovarian stimulation for in vitro fertilization:the Bologna criteria[J].Hum Reprod,2011,26(7):1616-1624
• [5] Kahyaoglu S,Yumusak OH,Ozgu-Erdinc AS,et al.Can serum estradiol levels on the fourth day of IVF/ICSI cycle predict outcome in poor responder women?[J].Syst Biol Reprod Med,2015,61(4):233-237
• [6] Revelli A,Biasoni V,Gennarelli G,et al.IVF results in patients with very low serum AMH are significantly affected by chronological age[J].J Assist Reprod Genet,2016,33(5):603-609
• [7] Scheffer JB,Scheffer BB,de Carvalho RF,et al.Age as a predictor of embryo quality regardless of the quantitative ovarian response[J].Int J Fertil Steril,2017,11(1):40-46
• [8] 杨菁,冯亭亭,孙伟,等.3种不同超促排卵方案在高龄患者体外受精-胚胎移植中的临床效果分析[J].现代妇产科进展,2016,25 (11):830-837
• [9] Kuang Y,Hong Q,Chen Q,et al.Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/ intracytoplasmic sperm injection treatment,with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles[J].Fertil Steril,2014,101(1):105-111
• [10] Zhu X,Zhang X,Fu Y.Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization[J].Med,2015,94(21):1-8
• [11] 朱秀娴,章晓乐,傅永伦.孕激素抑制LH峰在控制性卵巢刺激过程中的疗效观察[J].生殖与避孕,2015,35(6):384-388
• [12] 朱秀娴,陈秋菊,匡延平.卵巢功能正常患者使用不同促性腺激素联合安宫黄体酮促排卵的IVF/ ICSI - FET结局[J].生殖与避孕,2015,35(5):310-317
• [13] Venetis CA,Kolibianakis EM,Bosdou JK,et al.Progesterone elevation and probability of pregnancy after IVF:a systematic review and meta-analysis of over 60 000 cycles[J].Hum Reprod Update,2013,19(5):433-457
• [14] Kuang Y,Chen Q,Fu Y,et al.Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization[J].Fertil Steril,2015,104(1):62
• [15] Dong J,Wang Y,Chai WR,et al.The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilization:a randomised controlled trial[J].BJOG,2017,124(7):1048-1055
• [16] Zhu X,Ye H,Fu Y.Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation[J].Fertil Steril,2017,108(3):505-512
• [17] 何锦霞,赵琰,聂玲,等.3例卵巢低反应患者黄体期促排卵成功分析[J].江西医药,2013,48(12):1233-1234
• [18] 吕玉珍,朱光丽,宋文月.人工黄体期促排卵在卵巢储备功能低下患者中的应用[J].现代妇产科进展,2016,25(4):273-276
• [19] Sunkara SK,Coomarasamy A,Faris R,et al.Long gonadotropin-releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization:a randomized controlled trial[J].Fertil Steril,2014,101(1):147-153
• [20] Lefebvre J,Antaki R,Kadoch IJ,et al.450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders:a randomized controlled trial[J].Fertil Steril,2015,104(6):1419-1425
• [21] Reichman DE,Zakarin L,Chao K,et al.Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles[J].Fertil Steril,2014,102(1):99-102
• [22] 刘苡萱,朱旻,施敏凤,等.高孕激素状态促排卵(PPOS)方案在高龄卵巢低反应患者的促排卵研究[J].中国实验诊断学,2018,22(4):574-578
• [23] 奚倩雯,匡延平.高孕激素状态下促排卵-一种新的促排卵方案[J].中华生殖与避孕杂志,2018,38 (2):147-151
• [24] 沈秀,李颂军,邓伟芬,等.高孕激素下促排卵方案用于FSH升高DOR患者的临床效果观察[J].生殖医学杂志,2017,26(4):351-356
• [25] 王星祎,张翠莲,张少娣,等.高孕激素状态下促排卵方案(PPOS)与非典型微刺激方案在卵巢低反应患者体外受精-胚胎移植(IVF-ET)中的效果[J].生殖与避孕,2016,36(12):981-985